Novel and Future Directions in Cancer Pain Management (closed)
This session is currently closed, however, we suggest that you proceed on-site to the session for any available seating.
Lunch Satellite Symposium
Pain is often the first sign of cancer and most patients experience moderate to severe pain during the course of disease and into survivorship. The molecular, biochemical, and neurobiological mechanisms of cancerand metastatic cancer pain are being investigated, as are its geneticdeterminants. Molecular epidemiology provides insight into the interplay of genetic risk for cancer and risk for cancer symptoms. The undertreatment of cancer pain is well documented despite the availability of pharmacological options, including opioids, whose efficacy in cancer pain is well established. A new expert panel guideline on opioid rotation may advance clinical management of cancer pain.
Learning Objectives
1. Review molecular mechanisms of cancer pain.
2. Describe the role of genetic and nongenetic factors in predicting the severity of cancer pain and response to opioids.
3. Assess the role of opioids in the management of cancer pain, including new approaches to opioid rotation.
Faculty
Christine Miaskowski, RN, PhD, FAAN, Moderator
Patrick W. Mantyh, PhD, JD
Cielito C. Reyes-Gibby, DrPH
Oscar de Leon-Casasola, MD
This symposium is jointly sponsored by Postgraduate Institute for Medicine (PIM) and Miller Medical Communications, LLC. This session will offer continuing education for physicians, psychologists, nurses, and pharmacists. This symposium is supported by an educational grant from Endo Pharmaceuticals Inc. Participants with any questions regarding continuing education earned through participation in this symposium should contact Jennifer Jones at jjones@pimed.com.